SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on severe rare diseases and cancer. The company applies a precision medicine approach to develop and deliver life-changing medicines for individuals with these conditions. Since its establishment in 2017, SpringWorks has built a diversified targeted oncology pipeline that includes clinical trials for rare tumor types and genetically defined cancers.
Their first FDA-approved therapy, OGSIVEO®, is used to treat adult patients with progressing desmoid tumors requiring systemic treatment. SpringWorks’ strategic approach and operational expertise in clinical development have allowed them to advance lead product candidates into late-stage trials and establish collaborations with various industry and academic partners to maximize the potential of their portfolio and provide more solutions for cancer patients.
SpringWorks Therapeutics will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas, Nevada on May 14, 2024. The chat is scheduled for 3:40 p.m. PT / 6:40 p.m. ET and will be accessible via a live webcast on the Events & Presentations page on the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on the website for a limited time after the conference.
For more information about SpringWorks Therapeutics, visit www.springworkstx.com and follow @SpringWorksTx on social media platforms like X (formerly Twitter), LinkedIn, and YouTube
